A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer

The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy.Loco-regional recurrence constitutes the predominant failure patterns.Previous studies confirmed the relationship Kettle Brim Hat between increased biological equivalent doses and improved overall survival.

However, the large randomized phase III study, RTOG 0617, failed to demonstrate the benefit of dose-escalation to 74 Gy compared Riding Apparel - Tops - Sweatshirts and Pullovers with 60 Gy by simply increasing fraction numbers.

Leave a Reply

Your email address will not be published. Required fields are marked *